<iframe src="//www.googletagmanager.com/ns.html?id=GTM-MX3DVL" height="0" width="0" style="display:none;visibility:hidden"></iframe>Pestalozzi advised Johnson & Johnson Development Corporation (JJDC) in connection with Biocartis' series D fundraising | Pestalozzi Attorneys at Law

Pestalozzi advised Johnson & Johnson Development Corporation (JJDC) in connection with Biocartis' series D fundraising

12.2012

Biocartis, a molecular diagnostics company, completed a EUR 34.5 million Series D equity fund raising backed by existing investors. The round was led by the Flemish investment company PMV (using its TINA-fund), and included RMM (Rudi Mariën), Valiance, Debiopharm Group™, Korys (investment holding of the Colruyt family), Philips, JJDC, the family office of Dr. Paul Janssen, Luc Verelst, Benaruca (Rudi Pauwels, founder of Biocartis) and New Rhein Healthcare (Greg Parekh, CEO). Pestalozzi advised JJDC, the venture capital subsidiary of Johnson & Johnson, in this transaction like in previous equity financings relating to Biocartis in 2010 (Series B round) and 2011 (Series C round).

To the top